Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling

Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling

Buprenorphine readily crosses the placenta, and with greater prenatal exposure, neonatal opioid withdrawal syndrome (NOWS) likely grows more severe. Current dosing strategies can be further improved by tailoring doses to expected NOWS severity. To allow the conceptualization of fetal buprenorphine e...

Full description

Bibliographic Details
Main Authors: Matthijs W. van Hoogdalem, Ryota Tanaka, Khaled Abduljalil, Trevor N. Johnson, Scott L. Wexelblatt, Henry T. Akinbi, Alexander A. Vinks, Tomoyuki Mizuno
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Pharmaceutics
Subjects:
buprenorphine
maternal–fetal
physiologically based pharmacokinetic modeling
neonatal opioid withdrawal syndrome
opioid use disorder
Online Access:https://www.mdpi.com/1999-4923/16/3/375

Similar Items

Similar Items